TrialMolecular medicine (Cambridge, Mass.)2022

Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial.

Sergio Fragoso-Saavedra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.